. 2015 Mar 4;14:15. doi: 10.1186/s12944-015-0013-6

Table 6.

Effect of FVBM extract, F18 bioactive compound and atorvastatin on plasma triglycerides, total cholesterol and non-HDL-cholesterol in Triton WR-1339 induced hyperlipidemic rats after 18 hours of treatment

Group	Triglycerides	Total cholesterol	Non-HDL-cholesterol ^†
NC	60.45 ± 1.22*	75.86 ± 1.32	47.5 ± 1.17
HLC	240.74 ± 3.36*	361.92 ± 4.86	328.38 ± 3.6
HLC	(+298.24%)^a	(+377.08%)^a	(+591.32%)^a
FVT-1	95.47 ± 2.69*	126.17 ± 2.8	100.24 ± 2.5
FVT-1	(−60.34%)^a	(−65.13%)^a	(−69.47%)^a
FVT-2	65.42 ± 1.17*	84.25 ± 1.25	53.3 ± 1.19
FVT-2	(−72.82%)^a	(−76.79%)^a	(−83.76%)^a
CT	62.7 ± 1.48*	84.5 ± 2.25	55.8 ± 1.12
CT	(−73.95%)^a	(−76.65%)^a	(−83.00%)^a
AT	58.6 ± 1.15*	78.23 ± 1.25	49.6 ± 1.18
AT	(−75.65%)^a	(−78.38%)^a	(−81.85%)^a

^†For the calculation of non-HDL-C, data is taken from Tables 5 and 6.

^*Values are mean (mg/dl) ± SD from plasma of 5 rats in each group.

NC, normal control; HLC, triton induced hyperlipidemic control; FVT-1, fed 50 mg FVBM extract/ rat; FVT-2, fed 100 mg FVBM extract/ rat; CT, fed 1 mg F18 bioactive compound/ rat and AT, given 1 mg atorvastatin/rat once.

Significantly different from NC at ^ap < 0.001.

Significantly different from HLC at ^ap < 0.001.